Moreover, in subcutaneous tumor models, overexpression of TPX2 promoted the subcutaneous growth of HepG2 cells and sorafenib inhibited the subcutaneous growth of HepG2 cells in a dose-dependent manner (Fig. 6A–C). Here, TPX2 is linked to neoplasm.